HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Arrowhead Pharma (NASDAQ:ARWR) wit

Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses Cardiometabolic Pipeline and Clinical Development P

US stock futures up, Nasdaq 100 gains 1%. Biohaven (BHVN) shares down after BofA downgrade and enrol

Large-cap pharma is back in the deal market. AbbVie's (NASDAQ: ABBV | ABBV Price Prediction) pending

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that the European Commission (EC) has

Leerink Partners analyst Mani Foroohar maintains Arrowhead Pharma (NASDAQ:ARWR) with a Market Per

- Targeting Activin E may represent a novel therapeutic strategy for metabolic dysfunction-associate

Bernstein analyst William Pickering maintains Arrowhead Pharma (NASDAQ:ARWR) with a Market Perfor

RBC Capital analyst Luca Issi maintains Arrowhead Pharma (NASDAQ:ARWR) with a Outperform and rais

Arrowhead Pharma (NASDAQ:ARWR) reported quarterly losses of $(0.93) per share which beat the analyst

- Precision approach targets patients who have a mutation in the PNPLA3 gene, which is highly preval

Top Wall Street analysts changed outlooks on top names. Check analyst ratings page for all changes.

JP Morgan analyst Brian Cheng initiates coverage on Arrowhead Pharma (NASDAQ:ARWR) with a Overwei

– REDEMPLO is the first and only medicine approved for use in the treatment of FCS in Australia, and

– If confirmed by the European Commission, REDEMPLO would be the first and only siRNA medicine autho

Top Wall Street analysts changed outlook on top names. See analyst ratings page for all changes. Con

Wall Street analysts update ratings on top names. B of A Sec raised CMS Energy Corp's price targ

Morgan Stanley analyst Michael Ulz upgrades Arrowhead Pharma (NASDAQ:ARWR) from Equal-Weight to O

– Patients with severe hypertriglyceridemia (sHTG) achieved an 83% median reduction in triglycerides

Ionis Pharmaceuticals cuts Tryngolza price ahead of sHTG decision, with analysts seeing stronger sal

U.S. stocks rose, with the Dow Jones gaining 350 points on Wednesday. AAR Corp (NYSE: AIR) saw a 10.

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Arrowhead Pharma (NASDAQ:ARWR) wit

CRSP shares jump on earnings report, strong pipeline for gene therapy. Revenue grows with increased

CRISPR Therapeutics highlights progress in clinical trials & uptake of Casgevy gene therapy. Pip

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Arrowhead Pharma (NASDAQ:ARWR) wit

Arrowhead Pharma (NASDAQ:ARWR) reported quarterly earnings of $0.22 per share which beat the analyst

https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20260204-1482028/1482028_day5dva

- ARO-DIMER-PA is the first clinical candidate designed to silence the expression of two genes with

B. Riley Securities analyst Madison El-Saadi maintains Arrowhead Pharma (NASDAQ:ARWR) with a Buy

HC Wainwright & Co. analyst Patrick R. Trucchio maintains Arrowhead Pharma (NASDAQ:ARWR) with

Piper Sandler analyst Edward Tenthoff reiterates Arrowhead Pharma (NASDAQ:ARWR) with a Overweight

 Arrowhead Pharmaceuticals announced the pricing of its concurrent public offerings of (i) $625,000,

Goldman Sachs analyst Andrea Tan maintains Arrowhead Pharma (NASDAQ:ARWR) with a Neutral and rais

Morgan Stanley analyst Michael Ulz maintains Arrowhead Pharma (NASDAQ:ARWR) with a Equal-Weight a

Chardan Capital analyst Keay Nakae maintains Arrowhead Pharma (NASDAQ:ARWR) with a Buy and raises

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that the Chinese National Medical Prod

Arrowhead intends to use a portion of the net proceeds from the note offering to fund the cost of en

Arrowhead Pharmaceuticals reported early trial data showing notable reductions in body, liver, and v

ARO-INHBE in combination with tirzepatide achieved -9.4% weight loss at week 16 in obese patients wi

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that Health Canada has issued a Notic

Piper Sandler analyst Edward Tenthoff maintains Arrowhead Pharma (NASDAQ:ARWR) with a Overweight